Gables Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Gables Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.78K	Hold	200	–	–	﹤0.01%	413
2026 Q1	$6.02K	Hold	200	–	–	﹤0.01%	391
2025 Q4	$6.24K	Hold	200	–	–	﹤0.01%	384
2025 Q3	$4.04K	Hold	200	–	–	﹤0.01%	403
2025 Q2	$3.35K	Hold	200	–	–	﹤0.01%	399
2025 Q1	$3.07K	Hold	200	–	–	﹤0.01%	402
2024 Q4	$4.41K	Hold	200	–	–	﹤0.01%	396
2024 Q3	$3.6K	Hold	200	–	–	﹤0.01%	410
2024 Q2	$3.25K	Hold	200	–	–	﹤0.01%	361
2024 Q1	$2.82K	Hold	200	–	–	﹤0.01%	367
2023 Q4	$2.09K	Hold	200	–	–	﹤0.01%	360
2023 Q3	$2.04K	Hold	200	–	–	﹤0.01%	339
2023 Q2	$1.51K	Hold	200	–	–	﹤0.01%	359
2023 Q1	$1.77K	Hold	200	–	–	﹤0.01%	354
2022 Q4	$1.82K	Hold	200	–	–	﹤0.01%	337
2022 Q3	$2K	Hold	200	–	–	﹤0.01%	322
2022 Q2	$2K	Hold	200	–	–	﹤0.01%	336
2022 Q1	$2K	Hold	200	–	–	﹤0.01%	334
2021 Q4	$2K	Hold	200	–	–	﹤0.01%	333
2021 Q3	$2K	Hold	200	–	–	﹤0.01%	337
2021 Q2	$2K	Hold	200	–	–	﹤0.01%	338
2021 Q1	$2K	Hold	200	–	–	﹤0.01%	368
2020 Q4	$2K	Hold	200	–	–	﹤0.01%	347
2020 Q3	$2K	Sell	200 -3,000	-94%	-$31.7K	﹤0.01%	354
2020 Q2	$39K	Hold	3,200	–	–	0.03%	208
2020 Q1	$29K	Buy	3,200 +3,000	+1,500%	+$30.7K	0.02%	227
2019 Q4	$2K	Hold	200	–	–	﹤0.01%	337
2019 Q3	$1K	Hold	200	–	–	﹤0.01%	346
2019 Q2	$2K	Hold	200	–	–	﹤0.01%	328
2019 Q1	$3K	Hold	200	–	–	﹤0.01%	326
2018 Q4	$3K	Hold	200	–	–	﹤0.01%	335
2018 Q3	$4K	Hold	200	–	–	﹤0.01%	335
2018 Q2	$5K	Buy	+200	New	+$4.08K	﹤0.01%	333

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Gables Capital Management's TEVA Position: Q2 2026 in Review

Gables Capital Management held its Teva Pharmaceuticals (TEVA) position steady in Q2 2026 at 200 shares worth $6.78K. The position accounts for ﹤0.01% of the portfolio, ranked #413.

Gables Capital Management first reported a position in TEVA in Q2 2018 and has held it in 33 quarters since. The position peaked at $39K in Q2 2020. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

Gables Capital Management held 200 shares of Teva Pharmaceuticals worth $6.78K as of Q2 2026.
Gables Capital Management left its Teva Pharmaceuticals share count unchanged in Q2 2026.
Teva Pharmaceuticals made up ﹤0.01% of Gables Capital Management's portfolio in Q2 2026, its #413 holding.
Gables Capital Management first reported a position in Teva Pharmaceuticals in Q2 2018 and has held it in 33 quarters since.
Gables Capital Management's Teva Pharmaceuticals position peaked at $39K in Q2 2020.
672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Gables Capital Management's 13F filing for Q2 2026, filed 10 Aug 2026.